![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background: Invasive candidiasis is a major invasive fungal infection. It has high lethality, and even higher if not treated early. There is no consensus on antifungal treatment in patients with positive catheter tip culture for Candida spp. The objective of this study was to evaluate the impact of antifungal therapy and mortality of patients with positive culture for Candida spp. in catheter tip that have negative blood culture. Methods: The PubMed database was searched to identify articles related to Candida and catheter. Articles with adequate data were included. Results: Of 1208 studies initially screened, 5 met the selection criteria. All were retrospective studies. In all, 265 patients were evaluated for outcomes ‘candidemia’ and ‘invasive candidiasis’ and 158 for the outcome ‘mortality.’ Antifungal therapy had no impact on the development of invasive fungal disease (Odds ratio (OR) = 1.41; 95% confidence interval (CI) = 0.56–3.52). Also there was no benefit of therapy on mortality (OR = 1.02; 95% CI = 0.54–1.95). Conclusion: Due to the poor quality of the studies no conclusion can be made. Randomized prospective studies are needed to better evaluate this therapeutic strategy.
Declaration of interest: Bernardo de Almeida Machado and Giovanni L. Breda participate in clinical trials sponsored by Astellas, Merck, Pfizer, United Medical. Felipe F. Tuon receives Speaker’s fees (Bayer, Astra-Zeneca, Astellas, Merck, Pfizer, and Novartis). Flavio Queiroz-Telles is part of an advisory board of United Medical and TEVA and he also participates in clinical trials sponsored by Astellas, Pfizer, and MSD. No financial support was received for the present study.